$ALLO
Allogene Therapeutics, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018030022 Filed on November 21, 2018

View on sec.gov

Income Statement

Concept 2018 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.420M
YoY Change
% of Gross Profit
Research & Development $10.87M
YoY Change
% of Gross Profit
Depreciation & Amortization $500.0K
YoY Change
% of Gross Profit
Operating Expenses $22.19M
YoY Change
Operating Profit -$22.19M
YoY Change
Interest Expense $3.358M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$21.31M
YoY Change
Pretax Income -$43.50M
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$43.50M
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$377.5K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $244.2M
YoY Change
Cash & Equivalents $83.14M
Short-Term Investments $161.1M
Other Short-Term Assets $3.100M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $247.4M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $4.693M
YoY Change
Goodwill
YoY Change
Intangibles $904.0K
YoY Change
Long-Term Investments $154.0M
YoY Change
Other Assets $2.307M
YoY Change
Total Long-Term Assets $187.9M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $247.4M
Total Long-Term Assets $187.9M
Total Assets $435.2M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.083M
YoY Change
Accrued Expenses $16.80M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $139.6M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $159.5M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $7.488M
YoY Change
Total Long-Term Liabilities $7.488M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $159.5M
Total Long-Term Liabilities $7.488M
Total Liabilities $192.6M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$181.0M
YoY Change
Common Stock $12.72M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$168.4M
YoY Change
Total Liabilities & Shareholders Equity $435.2M
YoY Change

Cashflow Statement

Concept 2018 Q3
OPERATING ACTIVITIES
Net Income -$43.50M
YoY Change
Depreciation, Depletion And Amortization $500.0K
YoY Change
Cash From Operating Activities -$17.13M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$1.370M
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$315.4M
YoY Change
Cash From Investing Activities -$316.8M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 274.1M
YoY Change
NET CHANGE
Cash From Operating Activities -17.13M
Cash From Investing Activities -316.8M
Cash From Financing Activities 274.1M
Net Change In Cash -59.85M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$17.13M
Capital Expenditures -$1.370M
Free Cash Flow -$15.76M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83141000
CY2018Q3 us-gaap Short Term Investments
ShortTermInvestments
161080000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3132000
CY2018Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24996000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4693000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
247353000
CY2018Q3 us-gaap Long Term Investments
LongTermInvestments
154045000
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
904000
CY2018Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
937000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2307000
CY2018Q3 us-gaap Assets
Assets
435235000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3083000
CY2018Q3 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
16779000
CY2017Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
2000
CY2018Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
139615000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
159477000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2000
CY2018Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25661000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7488000
CY2018Q3 us-gaap Liabilities
Liabilities
192626000
CY2017Q4 us-gaap Liabilities
Liabilities
2000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
411052000
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
31000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2017Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
5000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
12693000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181019000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-148000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-168443000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
435235000
CY2018Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
11743987
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2018Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
11743987
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2018Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11743987
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2018Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
411770000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
101000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
47250000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31270573
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26249993
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31270573
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26249993
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10870000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
133356000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11317000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26440000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
22187000
us-gaap Operating Expenses
OperatingExpenses
159796000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22187000
us-gaap Operating Income Loss
OperatingIncomeLoss
-159796000
CY2018Q3 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
19415000
allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
19415000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3132000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1468000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
116842000
CY2018Q3 us-gaap Interest Expense
InterestExpense
3358000
us-gaap Interest Expense
InterestExpense
3358000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1463000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1573000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21310000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21200000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-43497000
us-gaap Net Income Loss
NetIncomeLoss
-180996000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-148000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-148000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43645000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-181144000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.71
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.38
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4060419
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11048451
us-gaap Profit Loss
ProfitLoss
-180996000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
109436000
us-gaap Share Based Compensation
ShareBasedCompensation
12695000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
302000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
651000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-125000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
664000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3358000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3083000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12695000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23172000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1913000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
315399000
us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
2098000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-319410000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
299282000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11375000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
839000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
426660000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
84078000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84078000
allo Convertible Preferred Stock Issued In Asset Acquisition
ConvertiblePreferredStockIssuedInAssetAcquisition
111770000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
25322000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
1388000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
204000
us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;letter-spacing:0.15pt;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the period from November&#160;30, 2017 (inception) to December&#160;31, 2017, the Company incurred $2,000 in start-up costs to establish the Company. Principal operations commenced in April 2018 when Allogene acquired certain assets from Pfizer Inc. (Pfizer) (see Note 6) and completed a Series A and A-1 preferred stock financing (see Note 10). </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public Offering</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold 20,700,000 shares of its common stock, which included 2,700,000 shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of $18.00 per share. As a result of the IPO, the Company received approximately $343.0 million in net proceeds, after deducting underwriting discounts and commissions of $26.1 million and offering expenses of approximately $3.5 million payable by the Company. At the closing of the IPO, 11,743,987 shares of outstanding convertible preferred stock were automatically converted into 61,655,922 shares of common stock and the 2018 Notes (see Note 9) were automatically converted into 7,856,176 shares of common stock. Following the IPO, there were no shares of preferred stock outstanding. As of September&#160;30, 2018, the Company had incurred $2.2 million of deferred offering costs, which will be offset against the net proceeds received from the sale of common stock. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Need for Additional Capital </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of&#160;$398.3&#160;million as of September&#160;30, 2018. Since inception through September&#160;30, 2018, the Company has incurred cumulative net losses of $181.0&#160;million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC). </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Forward Stock Split </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2018, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#8217;s common stock on a 1-for-5.25 basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</p>
CY2018Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.080
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2406000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4245000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-11-30
CY2017Q4 allo Start Up Cost
StartUpCost
2000000
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
398300000
CY2018Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2200000
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
394938000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
166000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
394790000
CY2018Q3 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P1Y6M3D
CY2018Q3 allo Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6584000
CY2018Q3 allo Unvested Shares Liabilities Current
UnvestedSharesLiabilitiesCurrent
3883000
CY2018Q3 allo Accrued Compensation And Related Benefits Current
AccruedCompensationAndRelatedBenefitsCurrent
1728000
CY2018Q3 allo Accrued Offering Costs Current
AccruedOfferingCostsCurrent
579000
CY2018Q3 allo Accrued Professional And Consulting Service Current
AccruedProfessionalAndConsultingServiceCurrent
2066000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1939000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000
CY2018Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
3258000
CY2018Q2 allo Discount Rate For Valuation
DiscountRateForValuation
0.165
CY2018Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4600000
CY2018Q3 allo Area Of New Office Building
AreaOfNewOfficeBuilding
68000
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P127M
CY2018Q3 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2029-02-28
CY2018Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2018Q3 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
5100000
CY2018Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
900000
CY2018Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y4M24D
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4394000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4548000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
31769000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
47362000
CY2018Q3 allo Operating Leases Future Minimum Payments Due Present Value Adjustment
OperatingLeasesFutureMinimumPaymentsDuePresentValueAdjustment
16596000
CY2018Q3 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
5105000
CY2018Q3 allo Operating Leases Future Minimum Payments Due Present Value
OperatingLeasesFutureMinimumPaymentsDuePresentValue
25661000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2018Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2018Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
120200000
CY2018Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
120200
CY2018Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
139600
CY2018Q3 us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
19400
us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
19400
CY2018Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3400000
CY2018Q2 allo Aggregate Purchase Price Shares Value
AggregatePurchasePriceSharesValue
300000000
CY2018Q3 us-gaap Temporary Equity Shares Subscribed But Unissued Subscriptions Receivable
TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable
150000000
allo Modification Of Convertible Preferred Stock For Common Stock
ModificationOfConvertiblePreferredStockForCommonStock
26249993
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
59500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
101810400000
CY2018Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
7500000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4639000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12695000
CY2018Q3 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
3900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
101810400000

Files In Submission

Name View Source Status
0001564590-18-030022-index-headers.html Edgar Link pending
0001564590-18-030022-index.html Edgar Link pending
0001564590-18-030022.txt Edgar Link pending
0001564590-18-030022-xbrl.zip Edgar Link pending
allo-10q_20180930.htm Edgar Link pending
allo-20180930.xml Edgar Link completed
allo-20180930.xsd Edgar Link pending
allo-20180930_cal.xml Edgar Link unprocessable
allo-20180930_def.xml Edgar Link unprocessable
allo-20180930_lab.xml Edgar Link unprocessable
allo-20180930_pre.xml Edgar Link unprocessable
allo-ex311_155.htm Edgar Link pending
allo-ex312_154.htm Edgar Link pending
allo-ex321_153.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending